D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

NRx Pharmaceuticals (NASDAQ:NRXP)‘s stock had its “buy” rating reissued by research analysts at D. Boral Capital in a report issued on Tuesday,Benzinga reports. They currently have a $34.00 price target on the stock.

A number of other equities analysts have also issued reports on NRXP. Zacks Research lowered NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. BTIG Research reiterated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research note on Thursday, January 15th. HC Wainwright restated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, January 21st. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NRx Pharmaceuticals in a report on Monday, December 29th. Four equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, NRx Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $36.75.

NRx Pharmaceuticals Price Performance

NRXP stock opened at $1.78 on Tuesday. The company has a market cap of $52.55 million, a price-to-earnings ratio of -0.76 and a beta of 1.91. The company has a fifty day moving average price of $2.19 and a 200 day moving average price of $2.56. NRx Pharmaceuticals has a 12 month low of $1.58 and a 12 month high of $3.84.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Ethos Financial Group LLC purchased a new stake in shares of NRx Pharmaceuticals during the 3rd quarter worth $39,000. Sjbenen Advisory LLC purchased a new position in shares of NRx Pharmaceuticals in the 4th quarter valued at about $41,000. One Wealth Management Investment & Advisory Services LLC lifted its stake in shares of NRx Pharmaceuticals by 86.1% in the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the period. Global Retirement Partners LLC purchased a new stake in NRx Pharmaceuticals during the fourth quarter worth about $107,000. Finally, Two Sigma Investments LP grew its position in NRx Pharmaceuticals by 66.4% during the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after buying an additional 20,880 shares during the period. Hedge funds and other institutional investors own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.